Ironwood Pharmaceuticals (NASDAQ: [[ticker:IRWD]]), the Cambridge, MA-based biotech company, said today that it passed its fourth major clinical trial of its lead drug candidate. The company, along with its partner Forest Laboratories, said that their experimental drug linaclotide showed a statistically significant benefit on all four primary study goals, when compared against a placebo for patients who have irritable bowel syndrome with constipation. The companies have now passed all four pivotal studies of linaclotide, which is designed for patients with chronic constipation, as well as irritable bowel syndrome with constipation. The companies plan to seek FDA clearance to start selling the product for both uses in 2011.
